{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:41:07Z","timestamp":1784551267630,"version":"3.55.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the effect of age and disease duration on the efficacy and safety of iGlarLixi versus insulin glargine 100\u2009units\/ml (iGlar) or lixisenatide (Lixi) alone in Asian people with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (LixiLan\u2010O\u2010AP) or basal insulin\u2009\u00b1\u2009oral antidiabetic drugs (LixiLan\u2010L\u2010CN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>In this post hoc analysis, the glycated haemoglobin (HbA1c) changes were assessed from baseline to week 24 (LixiLan\u2010O\u2010AP) or 30 (LixiLan\u2010L\u2010CN) in subgroups defined by baseline age (&lt;65, \u226565\u2009years) and duration of T2D. The proportion who achieved the composite of HbA1c &lt;7% (&lt;53.0\u2009mmol\/mol) without weight gain and without symptomatic hypoglycaemia (plasma glucose \u22643.9\u2009mmol\/L) and the incidences of hypoglycaemia and gastrointestinal disorders were also analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HbA1c reductions were consistently greater with iGlarLixi versus iGlar or Lixi across all subgroups, including participants aged \u226565\u2009years and those with T2D for \u226515 or \u226520\u2009years. Greater proportions of participants achieved HbA1c &lt;7% (&lt;53.0\u2009mmol\/mol) without weight gain or hypoglycaemia with iGlarLixi versus iGlar or Lixi, regardless of age or T2D duration. Hypoglycaemia incidence was similar with iGlarLixi versus iGlar across most subgroups; the incidence of gastrointestinal disorders was lower with iGlarLixi versus Lixi in all subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iGlarLixi showed consistent efficacy and safety across all age and disease duration subgroups in Asian people with uncontrolled T2D, including older individuals and those with longstanding disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15414","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T22:50:26Z","timestamp":1704322226000},"page":"1197-1206","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of age and disease duration on the efficacy and safety of\n                    <scp>iGlarLixi<\/scp>\n                    in Asian people with type 2 diabetes: A post hoc analysis of the\n                    <scp>LixiLan\u2010O\u2010AP<\/scp>\n                    and\n                    <scp>LixiLan\u2010L\u2010CN<\/scp>\n                    trials"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-9404","authenticated-orcid":false,"given":"Wenying","family":"Yang","sequence":"first","affiliation":[{"name":"China\u2010Japan Friendship Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Guo","sequence":"additional","affiliation":[{"name":"Peking University First Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Lauand","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Li","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexin","family":"Fang","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[{"name":"Sanofi  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Kang","sequence":"additional","affiliation":[{"name":"Sanofi  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"International Diabetes Federation.Diabetes atlas 10th edition.2021https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/. Accessed April 4 2023"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908292"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7596"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13759-9"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-09045-1"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dbi17-0013"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3158"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4729-5"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12886"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01126-x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.09.020"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1984"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14202"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S141235"},{"key":"e_1_2_10_16_1","unstructured":"National Medical Products Administration China.Delivery of drug approval certificates [in Chinese].2023.https:\/\/www.nmpa.gov.cn\/zwfw\/sdxx\/sdxxyp\/yppjfb\/20230113151759128.html. Accessed 19 July 2023."},{"key":"e_1_2_10_17_1","unstructured":"Pharmaceutical and Medical Devices Agency Japan.New drugs approved in FY 2019.2020.https:\/\/www.pmda.go.jp\/files\/000235289.pdf. Accessed 16 May 2023."},{"key":"e_1_2_10_18_1","unstructured":"US Food and Drug Administration.Soliqua\u00ae 100\/33 (Insulin Glargine and Lixisenatide) Injectin for Subcutaneous Use: Prescribing Information.2016.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/208673s012lbl.pdf. Accessed 16 May 2023."},{"key":"e_1_2_10_19_1","unstructured":"European Medicines Agency.Suliqua (insulin glargine and lixisenatide): summary of product characteristics.2017https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/suliqua\u2010epar\u2010product\u2010information_en.pdf. Accessed 16 May 2023."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0393"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-2452"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14036"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14005"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14722"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14803"},{"issue":"13","key":"e_1_2_10_29_1","first-page":"315","article-title":"Edition","volume":"2021","author":"Chinese Diabetes Society","year":"2020","journal-title":"Chin J Diabetes"},{"key":"e_1_2_10_30_1","unstructured":"The State Council: The People's Republic of China.Notice of the General Office of the State Council on issuing the National Health Plan for the 14th Five\u2010Year Plan [in Chinese].2022.https:\/\/www.gov.cn\/zhengce\/zhengceku\/2022\u201005\/20\/content_5691424.htm?eqid=fd5f6db300002dd3000000066463059a. Accessed 20 November 2023."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijge.2018.05.008"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108478"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13444"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2018.11.009"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14139"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14907"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:58Z","timestamp":1761870778000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/dom.15414"],"URL":"https:\/\/doi.org\/10.1111\/dom.15414","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15414\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15414\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15414\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15414\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15414\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15414\/v2\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"2023-10-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}